PRCT - PROCEPT BioRobotics hits post-IPO low as company named top M&A target for 2022

PROCEPT BioRobotics (PRCT -1.6%) hit a post-IPO low of $24.92 this morning despite a recent Goldman Sachs note calling the company a top M&A target in biopharma in 2022. PROCEPT is part of Goldman's Healthcare Strategic Assets Basket where analysts see a greater than 15% chance of M&A in the next 12 months. The company had its $165M IPO in September. Check out PROCEPT's Q3 2021 earnings.

For further details see:

PROCEPT BioRobotics hits post-IPO low as company named top M&A target for 2022